107 related articles for article (PubMed ID: 37248785)
21. Family history of breast cancer as a predictor for fatal prostate cancer.
Rodríguez C; Calle EE; Tatham LM; Wingo PA; Miracle-McMahill HL; Thun MJ; Heath CW
Epidemiology; 1998 Sep; 9(5):525-9. PubMed ID: 9730031
[TBL] [Abstract][Full Text] [Related]
22. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
23. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
24. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
25. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
[TBL] [Abstract][Full Text] [Related]
26. Population-based relative risks for specific family history constellations of breast cancer.
Albright FS; Kohlmann W; Neumayer L; Buys SS; Matsen CB; Kaphingst KA; Cannon-Albright LA
Cancer Causes Control; 2019 Jun; 30(6):581-590. PubMed ID: 31030355
[TBL] [Abstract][Full Text] [Related]
27. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
Claus EB; Stowe M; Carter D
Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
[TBL] [Abstract][Full Text] [Related]
28. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract][Full Text] [Related]
29. Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.
Beebe-Dimmer JL; Yee C; Cote ML; Petrucelli N; Palmer N; Bock C; Lane D; Agalliu I; Stefanick ML; Simon MS
Cancer; 2015 Apr; 121(8):1265-72. PubMed ID: 25754547
[TBL] [Abstract][Full Text] [Related]
30. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
Dite GS; Whittemore AS; Knight JA; John EM; Milne RL; Andrulis IL; Southey MC; McCredie MR; Giles GG; Miron A; Phipps AI; West DW; Hopper JL
Br J Cancer; 2010 Sep; 103(7):1103-8. PubMed ID: 20877337
[TBL] [Abstract][Full Text] [Related]
31. Psychological distress among healthy women with family histories of breast cancer: effects of recent life events.
Kim Y; Duhamel KN; Valdimarsdottir HB; Bovbjerg DH
Psychooncology; 2005 Jul; 14(7):555-63. PubMed ID: 15543540
[TBL] [Abstract][Full Text] [Related]
32. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
33. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
34. Family histories of breast cancer, coping styles, and psychological adjustment.
Kim Y; Valdimarsdottir HB; Bovbjerg DH
J Behav Med; 2003 Jun; 26(3):225-43. PubMed ID: 12845936
[TBL] [Abstract][Full Text] [Related]
35. Association between family history of prostate and breast cancer among African-American men with prostate cancer.
Beebe-Dimmer JL; Drake EA; Dunn RL; Bock CH; Montie JE; Cooney KA
Urology; 2006 Nov; 68(5):1072-6. PubMed ID: 17095075
[TBL] [Abstract][Full Text] [Related]
36. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
Yao L; Sun J; Zhang J; He Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Apr; 156(3):441-445. PubMed ID: 27033093
[TBL] [Abstract][Full Text] [Related]
38. First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
Ren ZJ; Cao DH; Zhang Q; Ren PW; Liu LR; Wei Q; Wei WR; Dong Q
BMC Cancer; 2019 Sep; 19(1):871. PubMed ID: 31477094
[TBL] [Abstract][Full Text] [Related]
39. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
